STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 24 - Issue 1, January-March 2022
SHORT REPORTS
INTRATHECAL TRASTUZUMAB PREPARATION FOR LEPTOMENINGEAL CARCINOMATOSIS SECONDARY TO DISTAL ESOPHAGEAL ADENOCARCINOM
GONZÁLEZ BARRIOS IVÁN, CORTIJO CASCAJARES SUSANA, SÁNCHEZ SANZ BEATRIZ, GOYACHE GOÑI MARÍA DEL PUY, LÓPEZ LÓPEZ FLORA, GÓMEZ MARTÍN CARLOS, HERNÁNDEZ RAMOS JOSÉ ANTONIO, FERRARI PIQUERO JOSÉ MIGUEL


Intrathecal trastuzumab was formulated for a patient with leptomeningeal carcinomatosis
secondary to esophageal adenocarcinoma. The literature review of prior experiences using intrathecal trastuzumab revealed that in most cases it has been used in patients with breast cancer. There is no evidence of use for esophageal carcinoma in the literature.
It was opted for the treatment of a patient with esophageal adenocarcinoma T 2-3 N1 M1 with mutation of the human epidermal growth factor receptor-2 (HER-2) associated with leptomeningeal carcinomatosis, thus stabilizing the disease during the weekly administration of 21 cycles. The importance of the article lies in its use in esophageal pathology and in that it describes the method of trastuzumab preparation according to the stipulations for the intrathecal route.

ESOPHAGEAL ADENOCARCINOMA – INTRATHECAL TRASTUZUMAB – LEPTOMENINGEAL CARCINOMATOSIS



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 33,88